Target intelligence / Profile preview

Pancreatic lipase enzyme (PL)

Target
PL
Molecular classification
Enzyme, Hydrolase, Lipase family, α/β-hydrolase fold protein
01

Overview

Pancreatic lipase is a key digestive enzyme secreted by the pancreas into the small intestine, where it catalyzes the hydrolysis of dietary triglycerides into monoglycerides and free fatty acids—an essential step for efficient fat absorption. Structurally, it consists of two domains: an N-terminal catalytic domain containing an α/β-hydrolase fold with a catalytic triad (serine 152, aspartic acid 176, histidine 263), and a C-terminal domain important for binding cofactors such as colipase. The enzyme's activity depends on interfacial activation—a conformational change that exposes its active site upon contact with lipid-water interfaces. Pancreatic lipase belongs to a broader family that includes hepatic and gastric/lingual lipases but has unique substrate specificity crucial for human nutrition. It serves as an important therapeutic target in obesity management through pharmacological inhibition.

Other names
Pancreatic triacylglycerol lipaseTriacylglycerol acyl hydrolasePTLEC 3.1.1.3
02

Mechanism of action

Inhibition of enzymatic hydrolysis of dietary triglycerides, reducing absorption of fats from the gastrointestinal tract

03

Biological functions

Hydrolysis of dietary triglycerides into monoglycerides and free fatty acidsFat digestion and absorption in the small intestineLipid metabolism
04

Disease associations

Obesity (targeted by anti-obesity drugs such as orlistat)Exocrine pancreatic insufficiency (deficiency leads to malabsorption)Other metabolic disorders related to fat digestion
05

Safety considerations

Gastrointestinal side effects with inhibitors like orlistat (e.g., steatorrhea, oily stools)Potential interference with absorption of fat-soluble vitamins when inhibited chronically
06

Interacting drugs

Orlistat
07

Biomarkers

No widely established biomarkers specific for patient selection or efficacy monitoring; however, fecal fat content can be monitored to assess enzyme activity indirectly in clinical settings.

Beyond the preview

Go deeper on Pancreatic lipase enzyme (PL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pancreatic lipase enzyme (PL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call